ijms-logo

Journal Browser

Journal Browser

Organoid Platforms for Personalized Medicine

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Biology".

Deadline for manuscript submissions: closed (31 March 2021) | Viewed by 3877

Special Issue Editors


E-Mail Website
Guest Editor
Centre for Cancer Biology, SA Pathology and the University of South of Australia, Adelaide, SA 5000, Australia
Interests: brain tumors; precision oncology; patient-derived organoids; transcriptomics; proteomics; deep learning; microscopy; brain disorders
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
1. Personalised Oncology Division, The Walter and Eliza Hall Institute of Medial Research, Parkville, VIC 3052, Australia
2. Department of Medical Biology, The University of Melbourne, Parkville, VIC 3052, Australia
Interests: bowel cancer genomics; cancer genetics; high-throughput molecular profiling; patient-derived organoids; bowel cancer biomarkers; drug screenings

Special Issue Information

Dear Colleagues,

Recent advances in stem cell and developmental biology have propelled the design of three-dimensional (3D) organoids that are able to mimic different organs in vitro, including the breast, brain, intestine, pancreas, prostate, amniotic sac, liver, gastric, and optical cup. These organoid models have been shown to be able to reflect human tissue during early embryogenesis, permitting the investigation of the interactions between different cell types within the developing organ as well as the self-organization processes that lead to its functional tissue cytoarchitecture and how the organ is affected in different developmental diseases. Moreover, patient-derived organoids (PDTO), including those derived by the culture of tumor biopsies, have been shown to not only recapitulate key aspects of the disease in vitro but also be predictive of the therapy response in patients, thus constituting an elemental tool for personalized medicine.

This Special Issue will be dedicated to publishing original work and reviews using organoids in the areas of pharmacology, bioinformatics, cell and cancer biology, drug screenings, bioengineering, genetics, etc. on aspects that will contribute to better understanding at the molecular level of human diseases, with potential applications in personalized medicine.

Dr. Guillermo Gomez
Prof. Oliver Sieber
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • organoid models of human disease
  • molecular mechanisms of human disease studied in organoids
  • molecular profiling and bioinformatic analysis of patient-derived organoids
  • precision medicine
  • drug testing and genetic manipulation in organoids
  • drug screenings in patient-derived organoids

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 5275 KiB  
Article
Epithelial Regeneration Ability of Crohn’s Disease Assessed Using Patient-Derived Intestinal Organoids
by Chansu Lee, Sung-Noh Hong, Eun-Ran Kim, Dong-Kyung Chang and Young-Ho Kim
Int. J. Mol. Sci. 2021, 22(11), 6013; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22116013 - 02 Jun 2021
Cited by 15 | Viewed by 3438
Abstract
Little is known about the ability for epithelial regeneration and wound healing in patients with inflammatory bowel diseases. We evaluated the epithelial proliferation and wound healing ability of patients with Crohn’s disease (CD) using patient-derived intestinal organoids. Human intestinal organoids were constructed in [...] Read more.
Little is known about the ability for epithelial regeneration and wound healing in patients with inflammatory bowel diseases. We evaluated the epithelial proliferation and wound healing ability of patients with Crohn’s disease (CD) using patient-derived intestinal organoids. Human intestinal organoids were constructed in a three-dimensional intestinal crypt culture of enteroscopic biopsy samples from controls and CD patients. The organoid-forming efficiency of ileal crypts derived from CD patients was reduced compared with those from control subjects (p < 0.001). Long-term cultured organoids (≥6 passages) derived from controls and CD patients showed an indistinguishable microscopic appearance and culturing behavior. Under TNFα-enriched conditions (30 ng/mL), the organoid reconstitution rate and cell viability of CD patient-derived organoids were significantly lower than those of the control organoids (p < 0.05 for each). The number of EdU+ cells was significantly lower in TNFα-treated organoids derived from CD patients than in TNFα-treated control organoids (p < 0.05). In a wound healing assay, the unhealed area in TNFα-treated CD patient-derived organoids was significantly larger than that of TNFα-treated control organoids (p < 0.001). The wound healing ability of CD patient-derived organoids is reduced in TNFα-enriched conditions, due to reduced cell proliferation. Epithelial regeneration ability may be impaired in patients with CD. Full article
(This article belongs to the Special Issue Organoid Platforms for Personalized Medicine)
Show Figures

Figure 1

Back to TopTop